Dare Bioscience Inc (DARE)

[harry crumb]

Roth capital has a 17$ price target up from 11$, im saying 3$ is very conservative

[harry crumb]

3$ is conservative pps

[nonsequetor]

DARE UP 15%

[nonsequetor]

Yes I am... get ready!

[nonsequetor]

DARE UP 10% GET ON BOARD!!!!

[nonsequetor]

Nice, steady movement upward.
What does Monday have in store?

[nonsequetor]

The spring is coiled and ready to release a whole lot of energy.

[Porterhouse10]

Jayzus and Baby Jayzus, you still in this?

[nonsequetor]

They tried to keep it down this morning but failed.
UP from here!

[nonsequetor]

NOOOOOOOOOOOOOOOOOOOOOOOOOOOO
If shares were still issued as certificates, this would be tucked away in the sock drawer.

[nonsequetor]

MAYBEEEEEEEEEEEEEE TODAYYYYYYYYYYYYYYY?????

[starkd748]

Lol

[nonsequetor]

I am going to initiate a subscription service based on my personal picks.

Whatever I recommend, do the opposite.

You will ALWAYS be a winner!!

[starkd748]

52 week lows coming

[nonsequetor]

It appears 1.36 was bottom.

We shall see...

[Porterhouse10]

Might be a good bottom, back watching, GLTY

[nonsequetor]

1.31-1.35 turnaround?

[nonsequetor]

Roth Capital just raised the PT from $11 to $17
SP is spiking

[nonsequetor]

ORGANON!

It should be an interesting day!

[nonsequetor]

2 more days...

[nonsequetor]

Some playing for pennies will get burned soon.

[Porterhouse10]

Pretty coiled up here

[nonsequetor]

Is this the week...?

[nonsequetor]

Biotechs appear to be the safe haven in this situation.

Loading up in a biotech with a strong pipeline and pending partnership is a no brainer.

Welcome new investors!

[nonsequetor]

Bucking the trend.

Many see the opportunity here...

[nonsequetor]

Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

https://finance.yahoo.com/news/organon-acquires-contraceptive-products-marvelon-133000574.html

[nonsequetor]

Daré Bioscience to Participate in Upcoming Conferences

https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-participate-upcoming-conferences

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming conferences:

2022 BIO CEO & Investor Conference
February 14-17, 2022, New York Marriott Marquis and Virtual
In-person Presentation Monday, February 14, 2022 at 2:15 p.m. EST

SVB Leerink Virtual 11th Annual Global Healthcare Conference
February 14-18, 2022, Virtual
Presentation Thursday, February 17, 2022 at 1:00 p.m. EST
Webcast link: https://wsw.com/webcast/svbleerink67/dare/2615800

An archived webcast of Ms. Johnson’s presentation at the SVB Leerink Virtual 11th Annual Global Healthcare Conference will be available until March 3, 2022 under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.

About Daré Bioscience

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.

Daré’s first FDA-approved product, XACIATOTM (clindamycin phosphate), is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s product portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about XACIATOTM, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
[e-mail]
212.213.0006

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Canale Communications
[e-mail]
619.849.5383

Source: Daré Bioscience, Inc.

[Porterhouse10]

Lol, no not me, but Damn!

[nonsequetor]

Did you just gulp up a half-mil?

ASK taken out up to 1.52 one hour ago

I was outside and missed all the action.

[nonsequetor]

and there we go... 1.38 arghhhhhhhhhhhhhhhh

I hope everyone got their fill.

It should be only up from here.

[nonsequetor]

I sincerely thought the bottom was in @1.59

Then, Biden, Putin, and the FED proved me wrong.

We shall see, but under 1.40 is a stretch...

heck

what do I know!

[Porterhouse10]

Almost pulled trigger @$1.51 yesterday, Markets are wack right now, Still watching closely, thx again

[nonsequetor]

We opened up a dock for a limited time only.

Take advantage while you can.

[Porterhouse10]

Looks like an interesting load zone

[nonsequetor]

We are on our way!

[harry crumb]

Hi folks, we entered. Not going to say to much other than have some patience with this. Could be an easy double here. GL $$$$$

[KeepOn]

Indeed.

[nonsequetor]

Maxim Group, this morning, raised their PT to $4 from $3.

[nonsequetor]

Indicators pointing to an interesting week.

[KeepOn]

Below the moving averages and trending upward. Good for longs, and maybe some short-term gains. Keeping on watch, for sure.

[nonsequetor]

All in today @1.59

Time to roll!

[nonsequetor]

Is today the day?

[nonsequetor]

CHUGGA-CHUGGA---CHOOOOOOOOOOOO CHOOOOOOOOOOO

I think I can... I think I can...

[nonsequetor]

Slowly but surely...

then

BOOM!!!

[Tom turtles]

I guess they need to fill the gap at $1.20

[Tom turtles]

Piece of garbage

[Tom turtles]

Garbage

[conix]

?Dawson James - Dare' (DARE) - XACIATO Approved

Daré announced that the FDA has approved XACIATO (clindamycin phosphate vaginal gel, 2%, formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.

Click here for the full report


BV1: A thermosetting bio-adhesive hydrogel formulated with clindamycin phosphate 2% as a first-line, single-administration treatment for bacterial vaginosis.

Market Opportunity? Bacterial vaginosis is the most common cause of vaginitis worldwide and is estimated to affect approximately 21 million women in the United States. Several therapeutic options for women exist but have insufficient clinical cure rates, require sequential daily administrations, or can be otherwise inconvenient for women to use. It is estimated that as many as 50% of women treated for bacterial vaginosis will experience a recurrence within 12 months of their treatment.

Price Target- No change. We have eliminated our therapeutic risk rate in our BV model but otherwise, our model and assumptions are unchanged. The effect on our valuation is de minimis.

Valuation: We assume that DARE-BV1 can be commercialized in 2022 and that Ovaprene can follow in the U.S. in 2023 and in the EU in 2025. For Sildenafil cream, we expect commercialization in the U.S. in 2024 and in the EU in 2025. We assume a 30% discount rate in our Free Cash Flow to the Firm (FCFF), Discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models due to the risks associated with each product. This results in models that are equally weighted and rounded to the nearest whole number for a $3.00 price target.

Risks to our thesis include: (1) commercial; (2) clinical and regulatory; (3) partnership; (4) financial; and (5) legal and intellectual property.

[Jake L]

DARE - Will Increase In Price Next Week

[GUBS59]

,,, Here's a nice Christmas present ... $9 P/S .....